Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor
The engineered CasX deal builds on the pharma’s 2020 Kiadis takeout
Sanofi’s deal with Scribe adds an optimized gene editing tool unencumbered by patent disputes to the pharma’s NK cell therapy arsenal.
Scribe Therapeutics Inc. said Tuesday it will grant Sanofi (Euronext:SAN; NASDAQ:SNY) non-exclusive rights to its CasX-Editor technology for multiple undisclosed oncology targets in engineered NK cell therapies. The gene editing company will receive $25 million up front, and is eligible for over $1 billion in milestone payments, plus tiered royalties...